Research
Hormonal
The combination of long-acting PYY analogs with a GLP-1 receptor agonist resulted in superior blood glucose lowering and greater body weight loss compared to GLP-1 alone.
Suggests a potential strategy for enhanced diabetes and obesity treatment.
StrongSupportsmedium confidence
these analogs showed superior blood glucose lowering in diabetic ZSF1 rats and greater body weight loss in a high-fat diet–induced mouse model of obesity compared with treatment with the GLP-1 analog alone.
Why this rating
Based on the comparative results provided in the abstract.
Source
Variant screening of PYY <sub>3–36</sub> leads to potent long-acting PYY analogs with superior Y <sub>2</sub> receptor selectivity
Søren Østergaard et al. · Science Translational Medicine · 2025
otherCited 8×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →